New Feature: Search Alerts are available now.
Learn more
.
Skip to main content
Create Account
About PLI PLUS
Help
Contact Us
Questions? Comments?
Contact us.
Email:
PLUS@pli.edu
Phone:
877.900.5291
PLI.edu
SIGN IN
Search
Browse
All Content
Books
- Answer Books
- Course Handbooks
- Journals
- News
- Treatises
Forms
Transcripts
My Bookshelf
My History
< Back To Results
1 in 1 results
Previous Result
Next Result
Cannabis: Business Fundamentals 2020
Chair(s):
Shabnam Malek
Practice Area:
Corporate & Securities, Health Care, Litigation
Published:
Apr 2020
ISBN:
9781402436260
PLI Item #:
278855
CHB Spine #:
B2560
This version is not current.
Click here for the most recent version.
Email
Print
Add To Bookshelf
Permalink
Table of Contents
Select All
Front Matter
Faculty Bios
Table of Contents
Chapter 1. Select Cannabis Legislation—2019–2020 Sessions (Substantive Outline) (February 2020)
Chapter 2. Gabriel Petek, How High? Adjusting California’s Cannabis Taxes (December 2019)
Chapter 3. Public Markets (Substantive Outline) (February 2020)
Chapter 4. Assembly Bill No. 2355, Introduced by Assembly Member Bonta (February 2020)
Chapter 5. Bureau of Cannabis Control, CEQA Exemption Petition Form
Chapter 6. Cannabis Regulations for CEQA Compliance and Shared-Use Facilities (March 2018)
Chapter 7. California Consumer Privacy Act (CCPA), Fact Sheet
Chapter 8. Memorandum (Substantive Outline) (February 2020)
Chapter 9. Patients: Create Patient/Customer
Chapter 10. Treez Sample
Chapter 11. Kiva Health Brands LLC v. Kiva Brands Inc., et al., Case 3:19-cv-03459-CRB (N.D. Cal. 2020)
Chapter 12. The Cannabis Act and Cannabis Regulations—Promotion Prohibitions
Chapter 13. Recreational Marijuana Program Compliance Education Bulletin
Chapter 14. Subchapter 5. Labeling and Packaging Requirements
Chapter 15. Clarification on Strain Names
Chapter 16. Hemp Industries Association v. Drug Enforcement Administration v. Drug Enforcement Administration,357 F.3d 1012 (9th Cir. 2004)
Chapter 17. In re Morgan Brown, No. 86362968 (T.T.A.B. July 14, 2016)
Chapter 18. California Legislative Information, Chapter 15. Advertising and Marketing Restrictions [26150–26156]
Chapter 19. California Legislative Information, Chapter 12. Packaging and Labeling [26120–26122]
Chapter 20. FDA U.S. Food and Drug Administration, Warning Letter, Nutra Pure LLC, CJ Montgomery
Chapter 21. FDA U.S. Food and Drug Administration, Warning Letter, PotNetwork Holdings, Inc., Gary Blum
Chapter 22. United States Patent and Trademark Office (USPTO), Nonfinal Office Action (September 10, 2019)
Chapter 23. 1402.01. Specifying the Goods and/or Services–In General
Chapter 24. 1402.03. Specificity of Terms Used in Identifying Goods and Services
Chapter 25. Cannabis: Business Fundamentals 2020 (Substantive Outline) (February 2020)
Chapter 26. Federal Food, Drug, and Cosmetic Act (FD&C Act)
Chapter 27. Federal Trade Commission, Truth in Advertising
Chapter 28. FDA News Release, FDA Warns 15 Companies for Illegally Selling Various Products Containing Cannabidiol as Agency Details Safety Concerns (November 25, 2010)
Chapter 29. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD)
Chapter 30. Examination Guide 1-19 (May 2, 2019)
Chapter 31. Rob Cerwinski, Brett Shuman, Daniel Mello and Nikhil Sethi, INSIGHT: Why the Illegality Doctrine Shouldn’t Apply to Cannabis Patents, The United States Law Week (January 17, 2020)
Chapter 32. Brett Schuman, Bill Growney and Nicholas Costanza, Handling the Valuation of Cannabis Companies for Private Equity and Venture Capital Clients, The Recorder (July 25, 2018)
Chapter 33. Brett Schuman and Khurram Naik, Law360, Cannabis Cos. Adopting Biotech’s Patent Playbook (January 25, 2019)
Chapter 34. Brett Schuman, Cynthia Hardman, Olivia Uitto and David Simson, Law360, Emerging Patent Issues in the Cannabis Industry (February 20, 2018)
Chapter 35. Overview of Civil Litigation and Disputes in the Cannabis Industry (Substantive Outline) (February 2020)
Chapter 36. Ethical Issues Related to the Representation of Cannabis Industry Clients (Substantive Outline) (February 2020)
Chapter 37. Title 21. United States Code (USC) Controlled Substances Act, Subchapter I—Control and Enforcement
Chapter 38. United States Drug Enforcement Administration, Drug Scheduling
Chapter 39. Garvin v. Cook Investments NW, et al., No. 18-35119 (9th Cir. 2019)
Chapter 40. In re: Way to Grow, Inc., et al., Case No. 18-14330 (Bankr. D. Colo. 2018)
Chapter 41. Additional Ethics Resources
Index
About Us
